%0 Journal Article
%T 卡瑞利珠单抗联合化疗与单纯化疗治疗III、IV期NSCLC疗效的Meta分析
Meta-Analysis of the Efficacy of Combined Camrelizumab and Chemotherapy versus Monotherapy with Chemotherapy in the Treatment of Stage III and IV Non-Small Cell Lung Cancer (NSCLC)
%A 王琳琳
%A 杜昌奇
%A 李红玲
%J Advances in Clinical Medicine
%P 2492-2499
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1441319
%X 目的:运用Meta分析方法系统评价卡瑞利珠单抗联合化疗治疗III、IV期非小细胞肺癌(NSCLC)的疗效及安全性。方法:检索CNKI、万方、中国生物医学文献服务系统、Pubmed,提取数据并进行核对,利用RevMan5.4软件Cochrane偏倚风险工具,对随机对照试验进行风险评估,并应用该软件进行Meta分析。结果:共纳入7个随机对照试验,包括463例患者。Meta分析结果显示:卡瑞利珠单抗联合化疗在客观缓解率[OR = 3.04, 95%CI (1.90, 4.85), P < 0.00001]、无进展生存期[MD = 2.12, 95%CI (1.64, 2.60), P < 0.00001]方面均高于单纯化疗组。结论:在III、IV期NSCLC的治疗中,卡瑞利珠单抗联合化疗的疗效优于单纯化疗组。
Objective: To systematically evaluate the efficacy and safety of camrelizumab combined with chemotherapy for the treatment of Stage III and IV non-small cell lung cancer (NSCLC) using a meta-analysis approach. Methods: Databases including CNKI, Wanfang, China Biological Medicine Database, and PubMed were searched. Data were extracted and cross-checked. The risk of bias in randomized controlled trials was assessed using the Cochrane Risk of Bias Tool in RevMan5.4 software. Subsequently, a meta-analysis was performed using the same software. Results: Seven randomized controlled trials involving a total of 463 patients were included. The results of the meta-analysis showed that compared to chemotherapy alone, the combination of camrelizumab and chemotherapy significantly improved the objective response rate [OR = 3.04, 95%CI (1.90, 4.85), P < 0.00001] and progression-free survival [MD = 2.12, 95%CI (1.64, 2.60), P < 0.00001]. Conclusion: In the treatment of Stage III and IV NSCLC, camrelizumab in combination with chemotherapy demonstrates superior efficacy over chemotherapy alone.
%K 卡瑞利珠单抗,非小细胞肺癌,化疗,随机对照试验
Camrelizumab
%K Non-Small Cell Lung Cancer
%K Chemotherapy
%K Randomized Controlled Trials
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=85714